semaglutide approved for mash approved MASH - Resmetirom Semaglutide Semaglutide Approved for MASH: A New Era in Liver Disease Treatment

Rezdiffra The U.S. Food and Drug Administration (FDA) has granted accelerated approval to semaglutide, in the form of Wegovy 2.4 mg injection, for the treatment of metabolic-associated steatohepatitis (MASH), also known as noncirrhotic MASH, with moderate to advanced liver fibrosis. This landmark decision marks the first time a Glucagon-like peptide-1 (GLP-1) receptor agonist has been approved for this specific liver condition, heralding a significant advancement in MASH treatment. The approval is specifically for adults with MASH who exhibit liver scarring, excluding cases with cirrhosis.Semaglutide Receives FDA Approval for Treatment of MASH

Understanding MASH and Its Progression

MASH is a serious, progressive form of non-alcoholic fatty liver disease (NAFLD) characterized by liver inflammation and damage, often accompanied by fibrosis (scarring)2025年8月22日—The FDA has granted acceleratedapprovalofsemaglutidefor the treatment ofMASHin adults with moderate to advanced fibrosis. Thisapprovalis .... If left untreated, MASH can advance to cirrhosis, liver failure, and increase the risk of liver cancer. The condition is closely linked to metabolic dysfunction, including obesity, type 2 diabetes, and dyslipidemia. Previously, treatment options for MASH were limited, often focusing on lifestyle modifications such as diet and exercise, and managing underlying metabolic conditions作者：S Petta·2025·被引用次数：7—Semaglutidehas recently received conditional acceleratedapprovalin the US for treatment of metabolic dysfunction-associated steatohepatitis (MASH) with ....

The Efficacy of Semaglutide in Clinical Trials

The approval of semaglutide for MASH is supported by robust clinical trial data, notably the Phase 3 ESSENCE trial.FDA approves weight loss jab to treat severe liver disease This pivotal study evaluated the efficacy and safety of semaglutide in adults with MASH and moderate to advanced liver fibrosisFDA Approval of Semaglutide for MASH Marks a Turning .... The trial demonstrated that weekly semaglutide 2.4 mg led to significant improvements in histological features of MASH, including resolution of MASH and a reduction in liver scarring.Phase 3 Trial of Semaglutide in Metabolic Dysfunction– ... A higher proportion of patients treated with semaglutide achieved resolution of MASH and improvement in fibrosis compared to placebo.

Specifically, the ESSENCE trial reported that semaglutide led to improvements in liver scarring and a higher proportion of patients achieving resolution of MASH as well as regression of fibrosis.Only Wegovy is officiallyapproved for MASH. The clinical trial exploring the use ofsemaglutideas a treatment forMASHis testing a weekly 2.4 milligram (mg) ... The clinical trial exploring the use of semaglutide as a treatment for MASH tested a weekly 2.4 milligram (mg) dose. This dosage is the same as that used for weight management in adults with obesity.

Wegovy: The First GLP-1 Receptor Agonist Approved for MASH

Wegovy (semaglutide) is now the first and only FDA-approved once-weekly GLP-1 RA medication indicated to treat adults with MASH and liver scarring, in conjunction with a reduced-calorie diet and exercise. This approval represents a significant milestone, offering a targeted therapeutic option for a condition that affects a substantial portion of the population. While other agents like Resmetirom and Rezdiffra have also received approval for MASH, Wegovy stands out as the first GLP-1 receptor agonist to gain this indication. It's important to note that semaglutide and Resmetirom are not approved for MASH cirrhosis, and thus should only be used among those with MASH without cirrhosis.

Expert Endorsement and Future Implications

Leading medical organizations, such as the American Association for the Study of Liver Diseases (AASLD), have applauded the FDA's approval of semaglutide for MASH. This approval is seen as a turning point in liver care, providing a much-needed therapeutic option for patients suffering from this debilitating disease. The semaglutide FDA approved MASH treatment signifies a move towards more personalized and effective interventions for liver conditionsWegovy approved for MASH | Nature Biotechnology. The use of semaglutide can lead to improved liver health outcomes and potentially reduce the progression to more severe liver diseases.

The approval of semaglutide for MASH is based on improvement of MASH and fibrosis, granted under accelerated approval based on these key findingsSemaglutide Receives FDA Approval for Treatment of MASH. This advancement is not only a victory for patients but also for ongoing research and drug development in the field of liver diseaseAASLD Releases Updated Practice Guidance on .... The successful application of semaglutide in preclinical mouse models, such as Gubra's GAN DIO-MASH model, further underscores its potential.

In conclusion, the FDA's approval of Wegovy (semaglutide) for MASH with liver fibrosis marks a new era in the management of this serious liver condition. This approved semaglutide MASH treatment offers hope and a tangible therapeutic path for millions of individuals affected by MASH worldwide.